CytoSorbents Q4/FY2025: Revenue $37.1M (+4% YoY), net loss improves to $8.2M; targets H2 2026 cash breakeven

Cytosorbents Corp

Revenue $37.1M (+4% YoY); gross margin 71%. Net loss improved to $8.2M ($0.13/sh) from $20.7M loss.
Adjusted net loss $14.2M ($0.23/sh) flat per share; adjusted EBITDA loss $10.5M improved from $11.5M.
Cash $7.8M at Dec 31, 2025; amended credit facility added $2.5M; workforce reduced 10% in Q4.
Targets cash flow breakeven in H2 2026; ongoing FDA discussions for DrugSorb-ATR De Novo submission (timing TBD).
Direct sales outside Germany +13%, distributor sales +11.4%; Germany sales -10% due to restructuring.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.